Nuvation Bio NUVB Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's deferred tax assets deferred expense capitalized research and development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's deferred tax assets deferred expense capitalized research and development costs?
- Nuvation Bio (NUVB) reported deferred tax assets deferred expense capitalized research and development costs of $78.79M in Q4 2025.
- How has Nuvation Bio's deferred tax assets deferred expense capitalized research and development costs changed year-over-year?
- Nuvation Bio's deferred tax assets deferred expense capitalized research and development costs decreased by 19.0% year-over-year, from $97.29M to $78.79M.
- What is the long-term trend for Nuvation Bio's deferred tax assets deferred expense capitalized research and development costs?
- Over 5 years (2020 to 2025), Nuvation Bio's deferred tax assets deferred expense capitalized research and development costs has grown at a 37.2% compound annual growth rate (CAGR), from $16.23M to $78.79M.
- What does deferred tax assets deferred expense capitalized research and development costs mean?
- This represents the tax benefit recognized from the capitalization of research and development expenditures that are amortized for tax purposes over time. It reflects the future tax savings expected as these capitalized costs are deducted from taxable income in subsequent periods. This metric is critical for biopharmaceutical companies to track the tax-related value of their ongoing investment in clinical-stage therapeutic candidates.